For all of the aforementioned reasons (employee compliance, time/cost considerations), but probably more importantly due to a large number of employees with a history of positive PPDs and/or BCG immunization, we switched all pre-employment screening to IGRA (Quantiferon).

 

Geoff Robinson PAC

Bristol Hospital – MedWorks

975 Farmington Avenue

Bristol, CT 06010

Phone: 860-589-0114

Fax: 860-589-1936

grobinso@bristolhospital.org

 

 

 

 

We went to Quantiferon Gold after doing time/cost analysis. It was actual less than half the cost when employee time and admin cost was factored.

 

We do not let new employees start until all on hire EHS criteria are met.

 

Other option is to email the employee’s manager that the employee needs to return to EHS for follow-up (not saying for what) and if manager’s initiative doesn’t work, go up the admin ladder until you get results.

 

Best of luck

 

Deborah A. Sampson, PhD, APRN, COHN-S, FAANP

Director

Employee Health and Wellness Services

Southern New Hampshire Health   P.O.Box 2014   8 Prospect Street   Nashua, NH 03060

p(603) 281-8583  f (603) 577-5665

deborah.sampson@snhhealth.org

 

 

 

 

 

 

 

 

My only suggestion is not to let them start working until both are complete. We are changing our policy because so much time is wasted on tracking them down, not to mention PPD solution and supplies.  Best wishes!

 

 

 

How does everyone get new hires to return for their second ppd?   It seems like we continually are trying track people down.  Any suggestions would be appreciated.

 

Thanks,

 

Linda Merz, M(ASCP)^CM, MLT, CIC

Manager, Infection Prevention & Control/

Employee Health & Wellness

314.525.1207

Linda.Merz@samcstl.org

 

If you could see the germs, you’d wash your hands

 

This e-mail may contain confidential information.  If you are not the intended recipient, promptly delete this message and notify the sender of the delivery error by return e-mail or call us at 314-525-1272.  You may not forward, print, copy, distribute, or use the information in this message if you are not the intended recipient.

 

DISCLAIMER: The information contained in this transmission may contain privileged and confidential information, including patient information protected by federal and state privacy laws. It is intended only for use by the intended recipient. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution, or duplication of this communication is strictly prohibited. The partaking of any action in reliance upon this information by persons or entities other than the intended recipient is illegal and a violation of the regulatory guidance in the Health Insurance Portability and Accountability Act (HIPAA). If you received this in error, please contact the sender immediately and delete the material from all computers.

Please Note: This e-mail transmission, including any attachments, is intended solely for the use of the individual(s) or organization(s) to which it is addressed. The information in this email, including attachments, may be confidential and/or privileged. If you are not a designated recipient, you are prohibited from reviewing, using, copying or distributing this message unless you receive express permission, in writing, from the sender or the designated recipient. If you received this e-mail in error, please notify the sender by reply e-mail and delete this e-mail from your system without copying it.